Recent Quotes
My Watchlist
Indicators
OGJ 150 Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

NeoGenomics, Inc. - Common Stock (NQ:NEO)

11.40 -0.08 (-0.70%)
Streaming Delayed Price Updated: 10:31 AM EST, Nov 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NeoGenomics, Inc. - Common Stock

< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
News headline image
Turnaround For This Cancer Genetics Testing Firm Could Take Years, Analyst Says While Downgrading Stock ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 22, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Target To $200? Here Are 5 Other Price Target Changes For Thursday ↗
Raymond James raised the price target on Target Corporation (NYSE: TGT) from $190 to $200. However, Raymond James analyst Bobby Griffin maintained the stock with a Strong Buy. Target shares fell 0.1%... 
Via Benzinga
News headline image
NeoGenomics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Via ACCESSWIRE
News headline image
NeoGenomics: Q2 Earnings Insights ↗
  NeoGenomics (NASDAQ:NEO) reported its Q2 earnings results on Tuesday, August 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
What 4 Analyst Ratings Have To Say About NeoGenomics ↗
  NeoGenomics (NASDAQ:NEO) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
NeoGenomics: Q2 Earnings Insights ↗
  NeoGenomics (NASDAQ:NEO) reported its Q2 earnings results on Tuesday, August 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Earnings Scheduled For August 12, 2022 ↗
Companies Reporting Before The Bell • NeoGenomics (NASDAQ:NEO) is projected to report quarterly earnings at $0.44 per share on revenue of $218.26 million. 
Via Benzinga
News headline image
NeoGenomics Reports Revenue of $125 Million in the Second Quarter
Via ACCESSWIRE
News headline image
NeoGenomics Announces Chief Executive Officer Appointment
Via ACCESSWIRE
News headline image
NeoGenomics Announces Chief Executive Officer Appointment
Chris Smith named CEO effective August 15, 2022; Interim CEO Lynn Tetrault to resume role of independent Chair of the Board 
From NeoGenomics, Inc.
Via AccessWire
News headline image
NeoGenomics Schedules its Second Quarter 2022 Earnings Release for August 9, 2022
FT. MYERS, FL / ACCESSWIRE / July 15, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing and global contract research services, announced today that it plans to... 
From NeoGenomics, Inc.
Via AccessWire
News headline image
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Its Investigation of NeoGenomics, Inc. (NEO) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
News headline image
INVESTOR ALERT: Law Offices of Howard G. Smith Continues Its Investigation of NeoGenomics, Inc. (NEO) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
The Law Offices of Frank R. Cruz Continues Its Investigation of NeoGenomics, Inc. (NEO) on Behalf of Investors
From Law Offices of Frank R. Cruz
Via Business Wire
News headline image
NeoGenomics Liquid Biopsy Subsidiary Inivata Announces New Data Demonstrating Clinical Potential of the RaDaR(TM) MRD Test in HR+ HER2- Breast Cancer
FT. MYERS, FL / ACCESSWIRE / June 21, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today confirms... 
From NeoGenomics, Inc.
Via AccessWire
News headline image
Lost Money in NeoGenomics, Inc.?
From Gibbs Law Group
Via Business Wire
News headline image
NeoGenomics To Participate In Multiple Upcoming Institutional Investor Conferences
FT. MYERS, FL / ACCESSWIRE / June 3, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced... 
From NeoGenomics, Inc.
Via AccessWire
News headline image
Analyst Ratings for NeoGenomics ↗
Over the past 3 months, 10 analysts have published their opinion on NeoGenomics (NASDAQ:NEO) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For June 3, 2022 ↗
 
Via Benzinga
News headline image
NeoGenomics Receives CAP Certification in their Suzhou China Pharma Services Laboratory
CAP Certification Expands Global Strategic Capabilities Supporting Biopharma R&D 
From NeoGenomics, Inc.
Via AccessWire
News headline image
NASDAQ:NEO Investor Alert: Investigation over Possible Wrongdoing at NeoGenomics, Inc. ↗
San Diego, CA -- (SBWIRE) -- 06/02/2022 -- Certain directors of NeoGenomics, Inc. are under investigation concerning potential breaches of fiduciary duties. 
Via SBWire
News headline image
Lost Money in NeoGenomics, Inc.?
From Gibbs Law Group
Via Business Wire
News headline image
Lost Money in NeoGenomics, Inc.?
From Gibbs Law Group
Via Business Wire
News headline image
NeoGenomics Appoints Lynn Tetrault Interim CEO
FT. MYERS, FL / ACCESSWIRE / May 16, 2022 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of cancer-focused genetic testing services and global oncology contract research services,... 
From NeoGenomics, Inc.
Via AccessWire
News headline image
Earnings Scheduled For May 13, 2022 ↗
Companies Reporting Before The Bell • Codere Online Luxembourg (NASDAQ:CDRO) is estimated to report quarterly loss at $0.13 per share on revenue of $20.08 million. 
Via Benzinga
News headline image
NeoGenomics, Inc. (NASDAQ: NEO) Investor Notice: Investigation over Possible Violations of Securities Laws ↗
San Diego, CA -- (SBWIRE) -- 05/11/2022 -- NeoGenomics, Inc is under investigation over potential securities laws violations in connection with certain financial statements. 
Via SBWire
News headline image
NeoGenomics Liquid Biopsy Subsidiary Inivata and Collaborators Present New Data Further Validating the Application of its RaDaR(R) MRD and InVisionFirst(R)-Lung Tests at the 2022 ASCO Annual Meeting
FT. MYERS, FL / ACCESSWIRE / May 10, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced... 
From NeoGenomics, Inc.
Via AccessWire
News headline image
NeoGenomics Announces Leadership Transition Appointing Vishal Sikri as President and Chief Commercial Officer of Inivata Liquid Biopsy Subsidiary
FT. MYERS, FL / ACCESSWIRE / May 9, 2022 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced the... 
From NeoGenomics, Inc.
Via AccessWire
News headline image
NeoGenomics To Participate in the BofA Securities 2022 Healthcare Conference
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence. 
From NeoGenomics, Inc.
Via AccessWire
< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
>